Accuitive Medical Ventures

Accuitive Medical Ventures is a venture capital firm based in Atlanta, founded in 2003. It specializes in financing and supporting the development of early and expansion stage companies within the medical device and technology sectors in the United States. By targeting innovative medical technology firms, Accuitive Medical Ventures aims to foster advancements that can improve healthcare outcomes.

Brandon Miller

Analyst

51 past transactions

MyoScience

Venture Round in 2018
MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

Intuity Medical

Debt Financing in 2018
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Sebacia

Series D in 2017
Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. The company aims to provide innovative alternatives to traditional topical and systemic medications by utilizing a patented technology involving gold microparticles. These microparticles are applied to the skin and activated using a standard dermatology laser, selectively targeting the structures involved in acne. Developed in collaboration with researchers from Rice University and the Wellman Center of Photomedicine at Massachusetts General Hospital, Sebacia's approach addresses unmet needs in dermatology while offering a more effective treatment option for those affected by acne. Established in 2008, Sebacia continues to advance its technology with the goal of improving patient outcomes.

Intuity Medical

Venture Round in 2016
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Torax Medical

Series E in 2016
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.

Sebacia

Series C in 2015
Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. The company aims to provide innovative alternatives to traditional topical and systemic medications by utilizing a patented technology involving gold microparticles. These microparticles are applied to the skin and activated using a standard dermatology laser, selectively targeting the structures involved in acne. Developed in collaboration with researchers from Rice University and the Wellman Center of Photomedicine at Massachusetts General Hospital, Sebacia's approach addresses unmet needs in dermatology while offering a more effective treatment option for those affected by acne. Established in 2008, Sebacia continues to advance its technology with the goal of improving patient outcomes.

AcuFocus

Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.

Intuity Medical

Venture Round in 2014
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

AqueSys

Series D in 2014
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, that specializes in developing and commercializing innovative implantable devices for glaucoma treatment. The company's primary product, the XEN gel stent, facilitates the outflow of aqueous humor from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure in patients with glaucoma. Established in 2005, AqueSys operates as a subsidiary of Allergan plc, focusing on addressing the challenges associated with managing glaucoma through its advanced medical technology. The XEN gel stent represents a significant advancement in glaucoma treatment, providing an alternative pathway for excess fluid to exit the eye and enhancing patient outcomes.

MyoScience

Series E in 2013
MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

Nevro

Series C in 2013
Nevro Corp. is a medical device company that focuses on developing innovative solutions for patients suffering from chronic pain. Based in Redwood City, California, the company has created the Senza spinal cord stimulation (SCS) system, which is an evidence-based neuromodulation platform that includes the proprietary HF10 therapy. This therapy provides electrical impulses to alleviate pain and is controlled by patients through a remote device. Nevro's product offerings extend to the Senza II and Senza Omnia systems, which are designed for chronic pain management. The company markets its products primarily in the United States and utilizes a direct sales force, along with a network of sales agents and independent distributors, to reach its customers. Founded in 2006, Nevro aims to enhance the quality of life for individuals affected by debilitating pain through its advanced medical technologies.

Torax Medical

Series D in 2012
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.

Intuity Medical

Venture Round in 2012
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Halscion

Debt Financing in 2012
Halscion, Inc. is focused on developing innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. The company produces single-use hydrogel scaffold devices that are injected during surgical procedures at the dermal-subdermal interface of wounds. These biocompatible materials create a structural framework that facilitates the migration and organization of the patient's own healing cells, such as fibroblasts, into the wound. This technology aims to prevent or minimize scar formation, including conditions like keloid and hypertrophic scars. Established in 2005, Halscion is headquartered in Suwanee, Georgia.

NeoVista

Venture Round in 2012
NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

WaveTec Vision

Venture Round in 2012
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

MyoScience

Series D in 2012
MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

AcuFocus

Venture Round in 2011
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.

Intuity Medical

Series D in 2011
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Nevro

Series B in 2011
Nevro Corp. is a medical device company that focuses on developing innovative solutions for patients suffering from chronic pain. Based in Redwood City, California, the company has created the Senza spinal cord stimulation (SCS) system, which is an evidence-based neuromodulation platform that includes the proprietary HF10 therapy. This therapy provides electrical impulses to alleviate pain and is controlled by patients through a remote device. Nevro's product offerings extend to the Senza II and Senza Omnia systems, which are designed for chronic pain management. The company markets its products primarily in the United States and utilizes a direct sales force, along with a network of sales agents and independent distributors, to reach its customers. Founded in 2006, Nevro aims to enhance the quality of life for individuals affected by debilitating pain through its advanced medical technologies.

WaveTec Vision

Series D in 2011
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

Halscion

Venture Round in 2011
Halscion, Inc. is focused on developing innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. The company produces single-use hydrogel scaffold devices that are injected during surgical procedures at the dermal-subdermal interface of wounds. These biocompatible materials create a structural framework that facilitates the migration and organization of the patient's own healing cells, such as fibroblasts, into the wound. This technology aims to prevent or minimize scar formation, including conditions like keloid and hypertrophic scars. Established in 2005, Halscion is headquartered in Suwanee, Georgia.

NeoVista

Series E in 2011
NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Respicardia

Series C in 2010
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

AqueSys

Series C in 2010
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, that specializes in developing and commercializing innovative implantable devices for glaucoma treatment. The company's primary product, the XEN gel stent, facilitates the outflow of aqueous humor from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure in patients with glaucoma. Established in 2005, AqueSys operates as a subsidiary of Allergan plc, focusing on addressing the challenges associated with managing glaucoma through its advanced medical technology. The XEN gel stent represents a significant advancement in glaucoma treatment, providing an alternative pathway for excess fluid to exit the eye and enhancing patient outcomes.

Halscion

Venture Round in 2009
Halscion, Inc. is focused on developing innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. The company produces single-use hydrogel scaffold devices that are injected during surgical procedures at the dermal-subdermal interface of wounds. These biocompatible materials create a structural framework that facilitates the migration and organization of the patient's own healing cells, such as fibroblasts, into the wound. This technology aims to prevent or minimize scar formation, including conditions like keloid and hypertrophic scars. Established in 2005, Halscion is headquartered in Suwanee, Georgia.

Sadra Medical

Series C in 2009
Sadra Medical is dedicated to creating innovative, minimally invasive alternatives to traditional surgical valve replacement, specifically targeting the treatment of aortic valve disease. The company aims to address the significant clinical need for effective therapies, as aortic valve stenosis affects approximately 3 million individuals in the United States, yet only a small percentage receive treatment through conventional open-heart surgery. By developing new devices that facilitate these advanced procedures, Sadra Medical seeks to enhance patient care and make valve replacement accessible to a broader range of patients. The company's goal is to reduce the risks and complications associated with open surgical procedures, providing a viable therapeutic option for those who currently lack effective treatment.

Torax Medical

Series C in 2009
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.

NovaLign Orthopaedics

Series B in 2009
NovaLign Orthopaedics formerly known as OsteoLign is an orthopaedic medical device company based in Memphis, Tenn. NovaLign recently received its first 510(k) clearance from the FDA to market its new Intramedullary Fixation System, a new system of implants and instruments for the treatment of long bone fractures, including the humerus, tibia and femur.

NeoVista

Series D in 2009
NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

WaveTec Vision

Series C in 2009
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

CELLutions Biosystems

Series B in 2008
Cellutions is developing proprietary medical devices and procedures to treat cellulite, a condition that affects 90% of post-adolescent females. The company is developing a proprietary technology/procedure to be performed in an outpatient setting as a minimally invasive ‘lunchtime' treatment.

Respicardia

Series B in 2008
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

Nevro

Series A in 2008
Nevro Corp. is a medical device company that focuses on developing innovative solutions for patients suffering from chronic pain. Based in Redwood City, California, the company has created the Senza spinal cord stimulation (SCS) system, which is an evidence-based neuromodulation platform that includes the proprietary HF10 therapy. This therapy provides electrical impulses to alleviate pain and is controlled by patients through a remote device. Nevro's product offerings extend to the Senza II and Senza Omnia systems, which are designed for chronic pain management. The company markets its products primarily in the United States and utilizes a direct sales force, along with a network of sales agents and independent distributors, to reach its customers. Founded in 2006, Nevro aims to enhance the quality of life for individuals affected by debilitating pain through its advanced medical technologies.

AqueSys

Series B in 2008
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, that specializes in developing and commercializing innovative implantable devices for glaucoma treatment. The company's primary product, the XEN gel stent, facilitates the outflow of aqueous humor from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure in patients with glaucoma. Established in 2005, AqueSys operates as a subsidiary of Allergan plc, focusing on addressing the challenges associated with managing glaucoma through its advanced medical technology. The XEN gel stent represents a significant advancement in glaucoma treatment, providing an alternative pathway for excess fluid to exit the eye and enhancing patient outcomes.

MyoScience

Series B in 2008
MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

AxoGen

Post in 2007
AxoGen, Inc. engages in the development of treatment options for the repair of peripheral nerve injuries. It offers AVANCE Nerve Graft, a human allograft nerve that is used for the repair, replacement, and reconstruction of damaged peripheral nerves. The company accepts orders through phone, fax, or email. It serves surgeons. AxoGen has a strategic tissue recovery partnership with American Tissue Services Foundation (ATSF). The company was founded in 2002 and is based in Alachua, Florida.

AqueSys

Series A in 2007
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, that specializes in developing and commercializing innovative implantable devices for glaucoma treatment. The company's primary product, the XEN gel stent, facilitates the outflow of aqueous humor from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure in patients with glaucoma. Established in 2005, AqueSys operates as a subsidiary of Allergan plc, focusing on addressing the challenges associated with managing glaucoma through its advanced medical technology. The XEN gel stent represents a significant advancement in glaucoma treatment, providing an alternative pathway for excess fluid to exit the eye and enhancing patient outcomes.

CELLutions Biosystems

Series B in 2007
Cellutions is developing proprietary medical devices and procedures to treat cellulite, a condition that affects 90% of post-adolescent females. The company is developing a proprietary technology/procedure to be performed in an outpatient setting as a minimally invasive ‘lunchtime' treatment.

WaveTec Vision

Series B in 2007
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

Inogen

Series D in 2007
Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.

AcuFocus

Series D in 2007
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.
Softscope Medical Technologies, founded in 2003 and based in Minnetonka, Minnesota, specializes in the development of endoscopic products. The company is dedicated to creating CROS enabled devices designed to facilitate the passage of a colonoscope, as well as CROS devices for small bowel enteroscopy.

NeoVista

Series C in 2006
NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Respicardia

Series A in 2006
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

NeoVista

Series B in 2006
NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Neuronetics

Series B in 2005
Neuronetics is a medical technology company based in Malvern, Pennsylvania, established in 2003. It specializes in developing non-invasive therapies for psychiatric and neurological disorders, particularly Major Depressive Disorder (MDD). The company's flagship product, the NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation (TMS) to deliver MRI-strength magnetic pulses that induce electrical currents in targeted areas of the brain associated with mood regulation. This innovative treatment is the first of its kind to receive FDA clearance for patients who have not found relief from traditional antidepressant therapies. Neuronetics aims to improve the quality of life for individuals suffering from mental health conditions through its advanced, non-systemic treatment options.

LipoSonix

Series C in 2004
LipoSonix, Inc. operates as a medical device company. The company develops non-invasive body sculpting products for aesthetic applications. The company was founded in 1999 and is based in Bothell, Washington. As of July 1, 2008, LipoSonix, Inc. operates as a subsidiary of Medicis Pharmaceutical Corp.

Inogen

Series B in 2004
Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.